Name (Synonyms) | Correlation | |
---|---|---|
drug1110 | Hydroxychloroquine Sulfate 400 mg twice a day Wiki | 1.00 |
drug628 | Conestat alfa Wiki | 1.00 |
drug1111 | Hydroxychloroquine Sulfate 600 mg once a day Wiki | 1.00 |
drug1853 | Placebo oral tablet Wiki | 0.19 |
Name (Synonyms) | Correlation | |
---|---|---|
D003141 | Communicable Diseases NIH | 0.09 |
D007239 | Infection NIH | 0.06 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.05 |
D018352 | Coronavirus Infections NIH | 0.04 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The PATCH trial (Prevention And Treatment of COVID-19 with Hydroxychloroquine) is funded investigator-initiated trial that includes 3 cohorts. Cohort 1: a double-blind placebo controlled trial of high dose HCQ as a treatment for home bound COVID-19 positive patients; Cohort 2: a randomized study testing different doses of HCQ in hospitalized patients; Cohort 3: a double blind placebo controlled trial of low dose HCQ as a preventative medicine in health care workers.
Description: Cohort 1 (home quarantined COVID-19 patients): Median time to release from quarantine by meeting the following criteria: 1) No fever for 72 hours 2) improvement in other symptoms and 3) 7 days have elapsed since the beginning of symptom onset.
Measure: Median release from quarantine time Time: 14 days or lessDescription: Cohort 2 (hospitalized COVID-19 patients): Rate of participants discharged at or before 14 days
Measure: Rate of hospital discharge Time: 14 daysDescription: Cohort 3 Physicians and nurse prophylaxis: Rate of COVID-19 infection at 2 months
Measure: Rate of infection Time: 2 monthsDescription: Cohort 1 rate of participant-reported secondary infection of housemates
Measure: Rate of housemate infection Time: 14 daysDescription: Cohort 1 rate of hospitalization
Measure: Rate of hospitalization Time: 14 daysDescription: Cohort 1 rate of treatment related adverse events
Measure: Cohort 1 adverse event rate Time: 14 daysDescription: Cohort 2 Time to condition appropriate for discharge. The primary care team indicates the patients has improved to the point of being discharged.
Measure: Time to condition appropriate for discharge Time: 14 daysDescription: Cohort 2 rate of ICU admission from a floor bed in the hospital
Measure: Rate of ICU admission Time: 14 daysDescription: Cohort 2 the number of days between hospital admission and a negative PCR test for SARS-CoV-2.
Measure: Time to PCR negativity Time: 14 daysDescription: Cohort 2 rate of treatment related adverse events
Measure: Cohort 2 adverse events Time: 14 daysDescription: Cohort 3 number of scheduled shifts at the hospital that are missed.
Measure: Scheduled shifts missed Time: 2 monthsDescription: Cohort 3 rate of treatment related adverse events
Measure: Cohort 3 adverse events Time: 2 months